Aberrant expression of BCL6B, frequently caused by promoter hypermethylation, is reported in several solid tumors, such as hepatocellular, gastric, breast, and colorectal cancers, as well as hematological malignancies. This evidence concerns the gene BCL6B and colorectal cancer.